Clinical trials: Newly Diagnosed
Newly Diagnosed FLT3 Mutated AML
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
A phase III randomized multi-center study designed to compare the efficacy of crenolanib with that of midostaurin when administered following induction chemotherapy, consolidation chemotherapy and bone marrow transplantation in…
- Trial name
- NCT03258931
- Testing
- Crenolanib, Midostaurin, Cytarabine
- Where
- 31 sites in United States
- Volunteers
- 214 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Pediatric Cancer Patients
Tissue Doppler Assessment of Right Ventricle Function in Pediatrics Underwent Chemotherapy
Tissue Doppler assessment of right ventricular function in newly diagnosed pediatric cancer patients underwent chemotherapy in South Egypt Cancer Institute.
- Trial name
- NCT04831359
- Testing
- Doppler ultrasound
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Glioblastoma Multiforme (GBM), Glioblastoma
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain, Glioblastoma, Adult
- Trial name
- CAPTEM (NCT03213002)
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Northwell Health
Type 1 Diabetes Mellitus
Rituximab in New Onset Type 1 Diabetes
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas.
- Trial name
- TN05 (NCT00279305)
- Testing
- Anti-CD20 (rituximab)
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 87 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Targeted Pediatric High-Grade Glioma Therapy
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05839379
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 350 people
- Sponsor
- Nationwide Children's Hospital
Acute Myeloid Leukemia
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial studies how well ASTX727 and venetoclax plus enasidenib works compared to ASTX727 and venetoclax alone for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML)…
- Trial name
- NCT06672146
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 138 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
NovoTTF-200A Together With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GBM
Study Objectives: To compare the efficacy and safety outcome of newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ to those treated with RT and TMZ alone Study Design: Prospective, randomized, open…
- Trial name
- NovoTTF-200A (NCT03869242)
- Testing
- NovoTTF-200A
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Prostate Cancer
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).
- Trial name
- ASCERTAIN (NCT05938270)
- Testing
- Saruparib (AZD5305), Darolutamide, No Treatment
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 113 people
- Sponsor
- AstraZeneca
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Acute Myeloid Leukemia
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
- Trial name
- NCT00373373
- Testing
- Sorafenib
- Where
- 18 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Muenster
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
This phase II trial studies the side effects of ibrutinib citrate when given with ixazomib, and determines how well they work in treating patients with Waldenstrom macroglobulinemia that is newly diagnosed, has come back…
- Conditions
- Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03506373
- Testing
- Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Prostate Cancer
PSMA Response in Metastasized Hormone Sensitive Prostate Cancer
PSMA-PET/CT response measurements after LHRH agonist and upfront therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.
- Trial name
- PET-MaN (NCT05161728)
- Testing
- PSMA-PET/CT
- Where
- 4 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Roderick van den Bergh
Glioblastoma
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
The phase I portion of study is designed to determine the Maximum Tolerated Dose (MTD) of BSI-201 with two clinically relevant dosing regimens of temozolomide (TMZ).
- Trial name
- NCT00687765
- Testing
- bsi-201 plus temozolomide
- Where
- 8 sites in United States
- Volunteers
- 126 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes
- Trial name
- NCT00778622
- Testing
- Metformin XR
- Where
- 14 sites in China
- Volunteers
- 371 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Lymphocytic, Acute, Adult
Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study
This is a prospective, multicenter, observational study aimed at exploring the efficacy and safety of reduced-dose chemotherapy followed by frontline therapy with blinatumomab in patients aged 15-65 with newly diagnosed…
- Trial name
- NCT06649422
- Testing
- Blinatumomab
- Volunteers
- 36 people
- Sponsor
- Shandong University
Ovarian Cancer, Fallopian Tube Cancer
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- IMagyn050 (NCT03038100)
- Testing
- Paclitaxel, Carboplatin, Atezolizumab
- Where
- 268 sites in United States, Australia and 20 more
- Volunteers
- 1,301 people
- Sponsor
- Hoffmann-La Roche
COVID-19, Corona Virus Infection
Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care
This study will assess the efficacy of hydroxychloroquine in reducing the severity of symptoms in patients with COVID-19
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV-2, 2019-nCoV
- Trial name
- NCT04334967
- Testing
- Hydroxychloroquine, Vitamin C
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Diffuse Intrinsic Pontine Glioma
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with…
- Trial name
- NCT04532229
- Testing
- Nimotuzumab+CRT(concurrent IMRT and TMZ)
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006353
- Testing
- temozolomide, radiation therapy
- Where
- 16 sites in Canada
- Volunteers
- 575 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer, Brain Metastases
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
The protocol is designed to determine the efficacy of temozolomide in preventing the development of new brain metastases within the first year in patients undergoing stereotactic radiation for newly diagnosed brain metastases.
- Trial name
- RAD0102 (NCT00582075)
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham